Peptomyc technology and IP is founded on the knowledge accumulated by Dr. Soucek‘s lab on Omomyc, a dominant-negative Myc mutant that is the most efficacious and safe direct Myc inhibitor to date and that shows great therapeutic promise in a variety -if not all- cancer types. Omomyc was considered a proof of principle for many years, and its application was to be limited to gene therapy. However, Dr. Soucek’s lab has shown...
Peptomyc technology and IP is founded on the knowledge accumulated by Dr. Soucek‘s lab on Omomyc, a dominant-negative Myc mutant that is the most efficacious and safe direct Myc inhibitor to date and that shows great therapeutic promise in a variety -if not all- cancer types. Omomyc was considered a proof of principle for many years, and its application was to be limited to gene therapy. However, Dr. Soucek’s lab has shown that the Omomyc peptide itself displays excellent cell penetrating properties and can efficiently enter cells and exert a strong anti-Myc activity that results in arrest/death of cancer cells.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.